Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAELYX vs Topotecan in Recurrent Ovarian Cancer
NCT01840943Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2013
- Primary completion
- May 2014
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 3 trial of pegylated liposomal doxorubicin in epithelial ovarian carcinoma (EOC), sponsored by Janssen Pharmaceutical. Started Jun 2013; status: terminated.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
epithelial ovarian carcinoma (EOC)
Beyond the preview
Go deeper on NCT01840943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01840943.